Core Viewpoint - Haizheng Pharmaceutical's subsidiary, Haizheng Hangzhou Company, has received the Certificate of Suitability to Monograph of European Pharmacopoeia (CEP) for its active pharmaceutical ingredient, Everolimus, indicating recognition of its quality in the European market and enhancing its qualifications for international market expansion [1] Group 1 - Haizheng Hangzhou Company has been awarded the CEP certificate by the European Directorate for the Quality of Medicines & HealthCare (EDQM) [1] - The CEP certification signifies that the quality of Everolimus meets European standards, allowing the product to enter the EU and other markets that recognize the CEP certificate [1] - This certification is expected to have a positive impact on the company's efforts to expand its international market presence [1]

Core Viewpoint - Zhejiang Haizheng Pharmaceutical Co., Ltd. has signed a project agreement with Zhejiang University for the development and industrialization of bio-synthesized anticoagulant heparin, with a total project amount of 120 million yuan, aiming to provide green innovative solutions for the global anticoagulant drug market [1][3]. Group 1: Market Context - The domestic heparin market has nearly reached 30 billion yuan, while the global market has surpassed 10 billion USD [3]. - The demand for heparin drugs is increasing due to factors such as an aging population, rising surgical procedures, and increasing chronic disease prevalence [3]. Group 2: Challenges in Traditional Production - Traditional heparin production relies on pig intestinal mucosa, leading to supply instability, quality fluctuations, and environmental pressures [3]. - The bio-synthesis method using microbial fermentation technology offers a sustainable supply of raw materials and significantly improves quality control [3]. Group 3: Company Expertise and Strategy - Haizheng Pharmaceutical has 69 years of experience in the pharmaceutical field and over 55 years of expertise in microbial technology [3]. - The collaboration will enhance Haizheng's product matrix in the anticoagulant drug sector, optimize existing industrial resources, and improve competitiveness in the high-end biopharmaceutical market [3][4]. Group 4: Project Significance - The bio-engineered heparin project is a core initiative of the research institute, marking a significant transition from laboratory research to industrial application [4]. - The partnership aims to disrupt traditional animal extraction methods for heparin production, facilitating a comprehensive process from laboratory research to mass production [4]. Group 5: Future Aspirations - The collaboration seeks to establish a globally leading research and production platform for anticoagulant drugs, filling the clinical application gap for bio-engineered heparin and providing safer and more effective treatment options for patients worldwide [5].

Core Viewpoint - Haizheng Pharmaceutical's wholly-owned subsidiary, Haizheng Hangzhou, has received a CEP certificate for Everolimus active pharmaceutical ingredient from EDQM, indicating the product's qualification for entry into the EU market, which will positively impact the company's international market expansion [1] Group 1 - Everolimus is applicable for various cancers and diseases related to tuberous sclerosis, and it can also prevent transplant rejection [1] - The global sales volume for Everolimus is projected to be approximately 128.81 kilograms in 2024, with an estimated 66.01 kilograms for the first half of 2025 [1] - The application for the CEP certificate was submitted on June 29, 2024, by Haizheng Hangzhou [1] Group 2 - The certification signifies the product's capability to enter international markets, which is expected to enhance the company's international business development [1] - However, there are risks associated with international business operations [1]

Core Viewpoint - Haizheng Pharmaceutical (600267.SH) has confirmed Guangzhou Medicine as the buyer in a property rights transaction, with a deposit of RMB 86 million paid for the acquisition of 100% equity in Zhejiang Pharmaceutical Industry Co., Ltd. [1] Group 1 - The company received a notification from the Taiwan Stock Exchange regarding the property rights transaction on December 10, 2025 [1] - The transaction is governed by the "Entrusted Transfer Service Agreement," "Bidding and Commitment," and "Online Bidding Transaction Guidelines" [1] - Guangzhou Medicine has submitted a total deposit of RMB 86 million for the equity transfer project [1]

浙江海正药业股份有限公司 关于全资子公司浙江省医药工业有限公司 100%股权 转让公开挂牌的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 浙江海正药业股份有限公司（以下简称"公司"）于 2025 年 8 月 22 日召开 的第十届董事会第六次会议审议通过了《关于公开转让全资子公司浙江省医药工 业有限公司 100%股权的议案》，同意公司通过公开挂牌方式对外转让全资子公 司浙江省医药工业有限公司（以下简称"省医药公司"）100%股权。公司已于 2025 年 11 月 10 日向台州市产权交易所有限公司（以下简称"台交所"）提交 了省医药公司 100%股权转让的挂牌申请，由台交所组织实施交易。具体详见公 司于 2025 年 8 月 26 日、2025 年 11 月 12 日披露的"临 2025-47 号"、"临 2025-68 号"公告。 2025 年 12 月 10 日，公司收到台交所出具的《产权交易签约通知函》（以 下简称"《通知函》"），根据《委托转让服务协议》、《竞买及承诺》和《网 络竞价交易须知》的规定，确认广 ...

Core Viewpoint - Haizheng Pharmaceutical (600267.SH) has confirmed that Guangzhou Medicine is the buyer in a property rights transaction, with a deposit of RMB 86 million paid for the acquisition of 100% equity in Zhejiang Pharmaceutical Industry Co., Ltd [1] Group 1 - The transaction is based on the "Entrusted Transfer Service Agreement," "Bidding and Commitment," and "Online Bidding Trading Instructions" [1] - The transaction notification was issued by the Taiwan Stock Exchange on December 10, 2025 [1]

Group 1: Major Transactions - Bohai Chemical is planning to sell 100% equity of Tianjin Bohai Petrochemical and acquire control of Anhui Taida New Materials through a combination of share issuance and cash payment, leading to a significant asset restructuring [1] - Zhongneng Electric is set to acquire 65% equity and debt from three companies, which may constitute a major asset restructuring but will not involve share issuance or change in control [4] - Hai Tai Development has decided to terminate the acquisition of controlling interest in Zhixueyun Technology due to disagreements on key terms, ensuring no adverse impact on normal business operations [5] Group 2: Performance Updates - Wen's shares reported a sales revenue of 3.324 billion yuan from meat chickens in November, marking a year-on-year increase of 10.18% [6] - Shuguang shares saw a 71.07% year-on-year increase in vehicle sales, totaling 207 units in November [6] - Muyuan shares experienced a decline in sales revenue from commodity pigs, reporting 9.39 billion yuan, a decrease of 20.43% year-on-year [6] - Pengding Holdings reported a 5.58% year-on-year decrease in consolidated revenue for November [6] Group 3: Industry Developments - Xiangxi Dairy reported a 6.3% month-on-month increase in fresh milk production in November, although it saw a year-on-year decline of 6.47% [7] - Baisheng Intelligent plans to acquire 51% equity in Zhongke Shengu, which focuses on the research and application of core technologies for embodied intelligent robots [7]

证券代码：600267 证券简称：海正药业 公告编号：临 2025-73 号 二、产品基本情况 猪支原体肺炎灭活疫苗（GD0503 株）适用于预防猪支原体肺炎（猪喘气病）， 接种后 28 日产生免疫力，免疫期为 6 个月。该疫苗产品通过使用猪肺炎支原体 GD0503 株接种 MH 培养基，收获培养物经浓缩、纯化、灭活后，加入油佐剂制 备而成。 2025 年 6 月 7 日，中华人民共和国农业农村部受理了云南生物递交的猪支 原体肺炎灭活疫苗（GD0503 株）产品批准文号申请。 截至目前，公司通过公开渠道未能获得市场其他公司上述同类产品具体销售 收入数据。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，浙江海正药业股份有限公司（以下简称"公司"）控股子公司浙江海 正动物保健品有限公司的全资子公司云南生物制药有限公司（以下简称"云南生 物"）收到中华人民共和国农业农村部核准签发的猪支原体肺炎灭活疫苗 （GD0503 株）兽药产品批准文号批件。现就相关情况公告如下： 一、批件基本信息 通用名称：猪支原体肺炎灭活疫苗（GD05 ...

Group 1 - The company, Zhejiang Haizheng Pharmaceutical Co., Ltd., announced that its wholly-owned subsidiary, Haizheng Nantong Co., Ltd., received a GMP compliance inspection notice from the Jiangsu Provincial Drug Administration [1] - The GMP inspection was conducted from October 31 to November 2, 2025, and concluded that the production lines and products met the required standards [1] - The inspection involved the production of Minocycline Hydrochloride, which is the first GMP compliance check for this product prior to its market launch [2] Group 2 - The production lines for Minocycline Hydrochloride have seen a total fixed asset investment of approximately 99.16 million yuan, with about 86.30 million yuan already completed [1] - Minocycline Hydrochloride is indicated for infections caused by various sensitive pathogens and was originally developed by Wyeth Pharmaceuticals [2] - In 2024, the global sales volume of Minocycline Hydrochloride was approximately 35,658.87 kg, with domestic sales accounting for about 7,914.50 kg [2]

Core Viewpoint - Haizheng Pharmaceutical (600267.SH) announced that its wholly-owned subsidiary, Haizheng Nantong Company, received a notice from the Jiangsu Provincial Drug Administration regarding the compliance inspection of drug GMP [1] Group 1: GMP Compliance Inspection - The GMP compliance inspection pertains to the active pharmaceutical ingredient Minocycline Hydrochloride, marking the first GMP compliance check prior to its market launch [1] - This inspection is the first for the newly established production line, which has now successfully passed the GMP compliance check [1] Group 2: Financial Investment - The total fixed asset investment in the relevant workshop has reached approximately 99.16 million yuan, with about 86.30 million yuan already completed (unaudited) [1]